Autonomic Nervous System Activity, Aging and Sleep Apnea/Hypopnea

Autonomic Nervous System Activity, Aging and Sleep Apnea/Hypopnea in a Prospective Cohort of Subjects Aged 67 Years

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00766584

Acronym

SYNAPSE

Enrollment

852

Registered

2008-10-06

Start date

2003-01-15

Completion date

2026-12-31

Last updated

2025-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Aging, Autonomic nervous system, stroke, Myocardiac infarction, Prospective cohort, Sleep apnea/hypopnea

Brief summary

The regulatory effects of the autonomic nervous system (ANS) concern almost all organs which permanently feed information back to this global biological vigilance system controlling allostasis. Heart rate fluctuations are highly dependent on ANS control, making the heart one of the best indicators of ANS activity. Low ANS activity level is associated with severe cardiac and cerebral events, as well as to death from any cause in the general population. It is even associated with sleep apnea/hypopnea.

Detailed description

The main goal of this SYNAPSE study is to evaluate, on a selected prospective cohort of subjects aged 67 years upon study entry, the incidence of sleep apnea/hypopnea and the prognostic values of ANS activity levels measured at preset times and of cardiovascular or cerebrovascular events.

Interventions

OTHERSleep apnea/hypopnea detection

Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

67 Years to 68 Years

Healthy volunteers

Yes

Inclusion criteria

* informed consent signed * to participate in the PROOF study

Exclusion criteria

* prior myocardiac infarction * prior stroke * hearth failure * atrial fibrillation * insulin-treated diabetes mellitus * cardiac pacemaker * disease limiting life expectancy to \< 5 years * contraindication to brain MRI * living in an institution * respiratory failure with oxygenotherapy * sleep-related breathing disorders known and treated

Design outcomes

Primary

Measure	Time frame
Composite criterion : fatal and non-fatal cardiovascular or cerebrovascular events	During all the study

Secondary

Measure	Time frame
Presence and relationship of sleep apnea/hypopnea and clinically silent stroke revealed through brain MRI	Years 1, 3, 5, 7 and 9

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026